Source: Eur Respir Rev 2016; 25: 223-226



Rating:

Share or cite this content

Citations should be made in the following way:
Frigerio Maria. Getting approval for new therapeutic medical devices versus drugs: are the differences justified?. Eur Respir Rev 2016; 25: 223-226

Member's Comments

No comment yet.

Related content which might interest you: The issues and the controversies: are we really ready for on-demand use of ICS? Source: Annual Congress 2013 –Inhaled corticosteroids for asthma: on-demand or continuous use? Year: 2013 Making clinical sense of the explosion in biologics - which drug for which patient and why? Source: International Congress 2019 – PG10 Severe asthma in adults: systematic assessment and biological treatment Year: 2019 Application of management guidelines to the assessment of new medicines: driving us forward or holding us back? Source: Eur Respir J 2004; 23: 793-794 Year: 2004 Prescriptions for treatment in patients with PCD: does clinical routine match recommendations? Source: Virtual Congress 2020 – Worldwide respiratory disease across the full spectrum Year: 2020 Evidence-based medicines for children: important implications for new therapies at all ages Source: Eur Respir J 2006; 28: 1069-1072 Year: 2006 Acceptance criteria for intensive care: we need new definitions and legislations for futile treatment! Source: International Congress 2017 – COPD and weaning Year: 2017 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Respiratory medicines for children: current evidence, unlicensed use and research priorities Source: Eur Respir J 2010; 35: 247-265 Year: 2010 Protocol of early mobilization and rehabilitation in critical patients using inotropic medications: Is it really safe? Our hands on practice! Source: International Congress 2019 – Exercise and rehabilitation in patients with acute and chronic respiratory diseases Year: 2019 Foundation doctor knowledge of inhaled devices - Are the old better than the new? Source: International Congress 2016 – Abstracts in medical education, the web and the internet Year: 2016 Biologics: current use and future applications for personalised therapy Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Who can pay for innovative medicines? Source: Eur Respir J 2013; 41: 495-496 Year: 2013 Preventing skin care issues associated with face masks used for domiciliary non-invasive ventilation: what do users and their carers think are the most relevant future research questions? Source: International Congress 2019 – Treatment of chronic respiratory failure with noninvasive ventilation Year: 2019 Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think? Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 The sustainability agenda and inhaled therapy: what do patients want? Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Do we need new antibiotics? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009